Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data

An existing physiologically based pharmacokinetic model for Di-(2-propylheptyl) phthalate (DPHP) was refined to improve the simulations of the venous blood concentrations of the primary monoester metabolite, mono-(2-propylheptyl) phthalate (MPHP). This was considered a significant deficiency that should be addressed because the primary metabolite of other high molecular weight phthalates has been associated with toxicity. The various processes that influence the concentration of DPHP and MPHP in blood were re-evaluated and modified. A few simplifications of the existing model were made, including the removal of enterohepatic recirculation (EHR) of MPHP. However, the primary development was describing the partial binding of MPHP to plasma proteins following uptake of DPHP and metabolism in the gut affording better simulation of the trends observed in the biological monitoring data. Secondly, the relationship between blood concentrations and the urinary excretion of secondary metabolites was explored further because the availability of two data streams provides a better understanding of the kinetics than reliance on just one. Most human studies are conducted with few volunteers and generally with the absence of blood metabolite measurements which would likely imply an incomplete understanding of the kinetics. This has important implications for the “read across” approach proposed as part of the development of New Approach Methods for the replacement of animals in chemical safety assessments. This is where the endpoint of a target chemical is predicted by using data for the same endpoint from another more “data rich” source chemical. Validation of a model parameterized entirely with in vitro and in silico derived parameters and calibrated against several data streams would constitute a data rich source chemical and afford more confidence for future evaluations of other similar chemicals using the read-across approach.

[1]  Weihsueh A. Chiu,et al.  Well-tempered MCMC simulations for population pharmacokinetic models , 2020, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  H. Koch,et al.  Hexamoll® DINCH and DPHP metabolites in urine of children and adolescents in Germany. Human biomonitoring results of the German Environmental Survey GerES V, 2014-2017. , 2020, International journal of hygiene and environmental health.

[3]  T. Brüning,et al.  Metabolism and urinary excretion kinetics of di(2-ethylhexyl) adipate (DEHA) in four human volunteers after a single oral dose. , 2019, Toxicology letters.

[4]  George Loizou,et al.  Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data , 2019, Front. Pharmacol..

[5]  R. Irizarry ggplot2 , 2019, Introduction to Data Science.

[6]  M. Kolossa-Gehring,et al.  Internal exposure of young German adults to di(2-propylheptyl) phthalate (DPHP): Trends in 24-h urine samples from the German Environmental Specimen Bank 1999-2017. , 2019, International journal of hygiene and environmental health.

[7]  R. Otter,et al.  Corrigendum to "Single ingestion of di-(2-propylheptyl) phthalate (DPHP) by male volunteers: DPHP in blood and its metabolites in blood and urine" [Toxicol. Lett. 294 (2018) 105-115]. , 2018, Toxicology letters.

[8]  T. Brüning,et al.  Bis-(2-propylheptyl)phthalate (DPHP) metabolites emerging in 24h urine samples from the German Environmental Specimen Bank (1999-2012). , 2015, International journal of hygiene and environmental health.

[9]  Céline Helbert,et al.  DiceDesign and DiceEval: Two R Packages for Design and Analysis of Computer Experiments , 2015 .

[10]  T. Brüning,et al.  Urinary metabolite excretion after oral dosage of bis(2-propylheptyl) phthalate (DPHP) to five male volunteers--characterization of suitable biomarkers for human biomonitoring. , 2014, Toxicology letters.

[11]  Virunya S Bhat,et al.  Derivation of an oral reference dose (RfD) for the plasticizer, di-(2-propylheptyl)phthalate (Palatinol® 10-P). , 2014, Regulatory toxicology and pharmacology : RTP.

[12]  Kevin McNally,et al.  PopGen: A virtual human population generator. , 2014, Toxicology.

[13]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[14]  W. Kessler,et al.  Kinetics of di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate in blood and of DEHP metabolites in urine of male volunteers after single ingestion of ring-deuterated DEHP. , 2012, Toxicology and applied pharmacology.

[15]  George Loizou,et al.  Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation , 2012, Journal of toxicology.

[16]  M. Katoh,et al.  Metabolite profiling and identification in human urine after single oral administration of DEHP. , 2012, The Journal of toxicological sciences.

[17]  T. Brüning,et al.  Assessing exposure to phthalates - the human biomonitoring approach. , 2011, Molecular nutrition & food research.

[18]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[19]  M. Wittassek,et al.  Phthalates: metabolism and exposure. , 2008, International journal of andrology.

[20]  Hadley Wickham,et al.  Reshaping Data with the reshape Package , 2007 .

[21]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[22]  G. Tucker,et al.  Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  G. Loizou,et al.  A human PBPK model for ethanol describing inhibition of gastric motility , 2004, Journal of Molecular Histology.

[24]  Ibrahim Chahoud,et al.  Blood burden of di(2-ethylhexyl) phthalate and its primary metabolite mono(2-ethylhexyl) phthalate in pregnant and nonpregnant rats and marmosets. , 2004, Toxicology and applied pharmacology.

[25]  B. Burchell,et al.  In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.

[26]  A. Saritelli,et al.  The in vitro serum protein-binding characteristics of bis-(2-ethylhexyl) phthalate and its principal metabolite, mono-(2-ethylhexyl) phthalate. , 1988, Environmental health perspectives.

[27]  N. Di Lascio,et al.  Tissue distribution of drug-metabolizing enzymes in humans. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[28]  U. Bondesson,et al.  Effects of di-(2-ethylhexyl) phthalate and five of its metabolites on rat testis in vivo and in in vitro. , 2009, Acta pharmacologica et toxicologica.

[29]  T. Orton,et al.  Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl) phthalate (DEHP) in rats and marmosets: extrapolation of effects in rodents to man. , 1986, Environmental health perspectives.

[30]  B. Lake,et al.  Studies on the testicular effects and zinc excretion produced by various isomers of monobutyl-o-phthalate in the rat. , 1981, Chemico-biological interactions.

[31]  S. Oishi,et al.  Testicular atrophy induced by phthalic acid monoesters: effects of zinc and testosterone concentrations. , 1980, Toxicology.